Sona test sensitivity & specificity07 Jul 2020 10:55
What keeps me firmly grounded about Sona's great test results is the fact that up to 35% of these tests performed with nasopharyngeal swab samples are estimated to be improperly performed, according to UK research. Must be the same in Canada, I suppose. So there must be a huge difference in the actual S&S % numbers when performed "in the field" vs in a lab where a trained technician is making sure the sample is applied correctly.
Where did you suddenly appear from, at this stage of GGP's evolution? And quite frankly, the analogy with Sxx is very wide of the mark. As an early investor in Sxx, in 2009, I knew most of the LTHs there, and many of us did very well indeed, thank you. Shades of GGP around 1p. The big differences were - a) one was debt financed, b) one is continually making new ATHs, the other making 5-year lows, c) II investments in one at these ATHs, d) manageable OPEX and CAPEX in one, thanks to proximity of a working plant, e) secular rising trend of one commodity, Gold, vs falling prices globally of the other, Potash.
RE: There's another aspect to the POC test demand....06 Jul 2020 20:31
Good evening RK.
That's interesting to know.
I forgot to mention the analogy of take-up of QLED TVs. It was thought that a price point of £1000 per tv would be that trigger point for surging demand. These are now selling at £599 in J Lewis, and Samsung sales are exploding. Case in point. Every product has one.
There's another aspect to the POC test demand....06 Jul 2020 20:14
...aside from which test is better, or faster, or more sensitive.
It is the price per test to the consumer (or non-medical user).
Sona's test is rumoured to be around $30-50 per test. Others, like the Becton Dickinson one mentioned today for airport use, is supposedly around the $100 mark.
These price points are simply too high and will not generate the millions, indeed billions, of repeat tests ordered from consumer markets globally. What we don't know yet is that price inflection point below which demand grows exponentially and sustainably, bringing forward a virtuous circle of high growth, lower per unit Opex, and super-profits (in the classic economic sense). Will that be $10 per test, or $5, or less?
We don't know yet, but my sense is that Medusa19 has a pretty good idea, and will reflect that to Avacta for consideration. They are consumer sales experts, something that diagnostic manufacturers typically are not.
LOL. This bb is hilarious. So much utter tripe posted by the usual ramping suspects, based on wrong inferences. All I can say to you, Riddler, is that if your ramping analysis is as flawed as your assertion that I am not already invested, based on my post earlier today, then God help you and your followers.
RE: This confirms it! Canadian report....05 Jul 2020 07:20
Well said, Jay.
There is a disturbing trend towards more authoritarian government around the Western world because of Covid-19. And towards big business as millions of SME face bankruptcy in the next few months because of lockdown policies everywhere. The Corporate State never had it so good.